InMed Pharmaceuticals Announces Granting of Patent for Novel Compounds
InMed Pharmaceuticals (NASDAQ: INM) has been granted its first international Patent Cooperation Treaty (PCT) patent in Mexico for novel cannabinoid analog compounds. The patent, titled 'Cannabinoid analogs and methods for their preparation', has a 20-year term and covers therapeutic applications for pain, glaucoma, inflammatory disease, anxiety, and neurological conditions including Parkinson's and Alzheimer's disease.
The patent protects both the compounds and their preparation methods, including drug candidates for Alzheimer's disease and dry age-related macular degeneration programs. The PCT application is pending in several additional jurisdictions including the U.S., Europe, and Japan. InMed currently maintains 14 patent families covering compositions, formulations, manufacturing processes, and methods of use.
InMed Pharmaceuticals (NASDAQ: INM) ha ricevuto il suo primo brevetto internazionale ai sensi del Trattato di Cooperazione in Materia di Brevetti (PCT) in Messico per nuovi composti analoghi ai cannabinoidi. Il brevetto, intitolato 'Analoghi dei cannabinoidi e metodi per la loro preparazione', ha una durata di 20 anni e copre applicazioni terapeutiche per dolore, glaucoma, malattie infiammatorie, ansia e condizioni neurologiche, tra cui il morbo di Parkinson e il morbo di Alzheimer.
Il brevetto protegge sia i composti che i loro metodi di preparazione, inclusi i candidati farmaci per il morbo di Alzheimer e i programmi per la degenerazione maculare secca legata all'età. La domanda PCT è in attesa in diverse giurisdizioni aggiuntive, tra cui gli Stati Uniti, l'Europa e il Giappone. InMed attualmente detiene 14 famiglie di brevetti che coprono composizioni, formulazioni, processi di produzione e metodi di utilizzo.
InMed Pharmaceuticals (NASDAQ: INM) ha recibido su primera patente internacional bajo el Tratado de Cooperación en materia de Patentes (PCT) en México para novedosos compuestos análogos de cannabinoides. La patente, titulada 'Análogos de cannabinoides y métodos para su preparación', tiene una duración de 20 años y cubre aplicaciones terapéuticas para dolor, glaucoma, enfermedades inflamatorias, ansiedad y condiciones neurológicas como la enfermedad de Parkinson y la enfermedad de Alzheimer.
La patente protege tanto los compuestos como sus métodos de preparación, incluidos los candidatos a fármacos para la enfermedad de Alzheimer y los programas de degeneración macular seca relacionada con la edad. La solicitud PCT está pendiente en varias jurisdicciones adicionales, incluidas EE. UU., Europa y Japón. Actualmente, InMed mantiene 14 familias de patentes que cubren composiciones, formulaciones, procesos de fabricación y métodos de uso.
InMed Pharmaceuticals (NASDAQ: INM)는 멕시코에서 새로운 칸나비노이드 유사 화합물에 대한 첫 국제 특허 협력 조약(PCT) 특허를 승인받았습니다. '칸나비노이드 유사물질 및 그 준비 방법'이라는 제목의 이 특허는 20년의 유효 기간을 가지며 통증, 녹내장, 염증성 질병, 불안 및 신경학적 상태, 파킨슨병과 알츠하이머병을 포함한 치료적 응용을 다룹니다.
이 특허는 화합물과 그 준비 방법을 모두 보호하며 알츠하이머병 및 건성 노화 관련 황반 변성 프로그램에 대한 약물 후보를 포함합니다. PCT 신청은 미국, 유럽 및 일본을 포함한 여러 추가 관할권에서 대기 중입니다. InMed는 현재 14개의 특허 군을 보유하고 있습니다.
InMed Pharmaceuticals (NASDAQ: INM) a obtenu son premier brevet international conformément au Traité de coopération en matière de brevets (PCT) au Mexique pour des composés analogues de cannabinoïdes novateurs. Le brevet, intitulé 'Analogues de cannabinoïdes et méthodes de préparation', a une durée de 20 ans et couvre des applications thérapeutiques pour douleur, glaucome, maladies inflammatoires, anxiété et conditions neurologiques, y compris la maladie de Parkinson et la maladie d'Alzheimer.
Le brevet protège à la fois les composés et leurs méthodes de préparation, y compris des candidats-médicaments pour la maladie d'Alzheimer et des programmes concernant la dégénérescence maculaire sèche liée à l’âge. La demande PCT est en attente dans plusieurs autres juridictions, y compris les États-Unis, l'Europe et le Japon. InMed détient actuellement 14 familles de brevets couvrant des compositions, des formulations, des processus de fabrication et des méthodes d'utilisation.
InMed Pharmaceuticals (NASDAQ: INM) hat in Mexiko sein erstes internationales Patent gemäß dem Patentzusammenarbeitstraktat (PCT) für neuartige Cannabinoid-Analogverbindungen erhalten. Das Patent mit dem Titel 'Cannabinoid-Analoga und Methoden zu deren Herstellung' hat eine Laufzeit von 20 Jahren und deckt therapeutische Anwendungen für Schmerzen, Glaukom, entzündliche Erkrankungen, Angstzustände und neurologische Erkrankungen, einschließlich Parkinson- und Alzheimer-Krankheit, ab.
Das Patent schützt sowohl die Verbindungen als auch deren Herstellungsmethoden, einschließlich Arzneikandidaten für Alzheimer und Programme zur trockenen altersbedingten Makuladegeneration. Der PCT-Antrag wird in mehreren weiteren Jurisdiktionen, einschließlich der USA, Europa und Japan, geprüft. InMed besitzt derzeit 14 Patentfamilien, die Zusammensetzungen, Formulierungen, Herstellungsverfahren und Verwendungsweisen abdecken.
- Secured 20-year patent protection for novel compounds in Mexico
- Patent portfolio includes 14 patent families covering multiple aspects of drug development
- Patent applications pending in major markets (US, Europe, Japan)
- Protection covers both compounds and manufacturing methods
- Patent only granted in Mexico so far, pending in major markets
- No immediate revenue impact from patent grant
Insights
The granting of this Patent Cooperation Treaty (PCT) patent in Mexico represents a strategic milestone for InMed Pharmaceuticals' intellectual property portfolio. While Mexico may not be the largest pharmaceutical market, securing this first jurisdictional approval typically accelerates subsequent approvals in major markets like the US, Europe and Japan, where applications are pending.
The patent's broad scope is particularly noteworthy, covering both novel compounds and manufacturing methods for multiple high-value therapeutic areas including Alzheimer's, Parkinson's and inflammatory diseases. This comprehensive protection creates significant barriers to entry for competitors and positions InMed favorably for potential licensing deals or partnerships.
The company's robust patent strategy, encompassing 14 patent families, demonstrates a sophisticated approach to IP protection across multiple layers:
- Compound composition and analogs
- Manufacturing processes and biosynthesis methods
- Specific therapeutic applications and delivery systems
- Formulation technologies
For a small-cap pharmaceutical company (
However, investors should note that patent protection, while necessary, is just one step in the complex and costly drug development process. The company will need substantial capital to advance its candidates through clinical trials and success in securing additional patents in major markets will be important for long-term value creation.
Marks the first jurisdictional issuance of an international patent for a family of novel small molecule compounds
Patent covers novel analog compounds for therapeutic applications in pain, glaucoma, inflammatory disease, anxiety, and a variety of neurological conditions including Parkinson's disease, Alzheimer's disease and dementia
Patent also protects the methods of preparation of the compounds
Vancouver, British Columbia--(Newsfile Corp. - January 22, 2025) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today announces it has been granted an international Patent Cooperation Treaty ('PCT') patent in the first of several jurisdictions where the patent has been filed.
Titled "Cannabinoid analogs and methods for their preparation", this patent protects the use of several proprietary small molecule compounds and methods of their preparation, including the drug candidates screened for InMed's Alzheimer's disease and dry age-related macular degeneration programs. This Patent No. 417531 (Application No. MX/a/2021/005026) has been issued in Mexico and holds a 20-year term. The initial jurisdictional issuance of this important patent strengthens InMed's intellectual property portfolio, ensuring the protection of innovative cannabinoid analogs designed for diverse therapeutic applications, including neurological disorders, behavioral conditions, inflammation, and other medical needs. The PCT patent further protects InMed's production methods of its novel pharmaceutical drug development candidates utilizing modern biopharmaceutical manufacturing approaches. The international PCT application has been filed in, and is awaiting issuance from, several additional jurisdictions including the U.S., Europe, Japan and others.
InMed's President and CEO, Eric A. Adams, said, "We are pleased with this initial issuance of a key PCT patent for our proprietary small molecule drug development candidates. Our innovation includes an extensive library of novel small molecules aimed at targeting specific pharmacological properties for therapeutic application. This has led to the development of promising, novel drug candidates for Alzheimer's disease and age-related macular degeneration." He added, "The issuance underscores our commitment to securing the long-term intellectual property protection of our research and development efforts. We remain focused on expanding our patent portfolio to protect our novel drug candidates, methods of manufacturing these drugs, how they are formulated and how they are used to support the development of new treatments for diseases with high unmet medical needs."
InMed has a total of 14 patent families covering compositions, formulations, manufacturing processes and methods of use.
Summary of Granted Patents (to date):
| Subject Matter | Scope | Status and jurisdiction |
| Cannabinoid analogs and methods of their preparation | Formulation, manufacturing processes | Granted: Mexico Pending: Several jurisdictions |
| Use of topical formulations of cannabinoids in the treatment of epidermolysis bullosa and related connective tissue disorders | Method of Use | Granted: US, Australia, Japan, Israel Pending: Several jurisdictions |
| Metabolic engineering of E. coli for the biosynthesis of cannabinoid products | Manufacturing Process | Granted: U.S. Pending: Several jurisdictions |
| Ocular drug delivery formulation | Formulation, Method of Use | Granted: Australia, Japan, India, Europe, U.S. |
| Recombinant production systems for prenylated polyketides of the cannabinoid family | Manufacturing Process | Granted: U.S., Mexico Pending: Several jurisdictions |
About InMed:
InMed Pharmaceuticals is a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates targeting the CB1/CB2 receptors. InMed's pipeline consists of three separate programs in the treatment of Alzheimer's, ocular and dermatological indications. Together with our subsidiary BayMedica, we are a global leader in the manufacturing, development and commercialization of rare cannabinoids and proprietary small molecule drug candidates. For more information, visit www.inmedpharma.com.
Investor Contact:
Colin Clancy
Vice President, Investor Relations
and Corporate Communications
T: +1 604 416 0999
E: IR@inmedpharma.com
Cautionary Note Regarding Forward-Looking Information:
This news release contains "forward-looking information" and "forward-looking statements" (collectively, "forward-looking information") within the meaning of applicable securities laws. Forward-looking statements are frequently, but not always, identified by words such as "expects", "anticipates", "believes", "intends", "potential", "possible", "would" and similar expressions. Such statements, based as they are on current expectations of management, inherently involve numerous risks, uncertainties and assumptions, known and unknown, many of which are beyond our control. Forward-looking information is based on management's current expectations and beliefs and is subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Without limiting the foregoing, forward-looking information in this news release includes, but is not limited to, statements about: pursuing new chemical entity patents on the drug candidates for both its INM-901 program in Alzheimer's disease and INM-089 in dry Age-related Macular Degeneration; continuing to build a patent portfolio to protect of composition of matter, formulations, manufacturing processes and methods of use.
Additionally, there are known and unknown risk factors which could cause InMed's actual results, performance, or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information contained herein. A complete discussion of the risks and uncertainties facing InMed's stand-alone business is disclosed in InMed's Annual Report on Form 10-K and other filings with the Securities and Exchange Commission on www.sec.gov.
All forward-looking information herein is qualified in its entirety by this cautionary statement, and InMed disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except as required by law.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/238045
FAQ
What therapeutic applications are covered by InMed's (INM) new patent?
How long is the term of InMed's (INM) new Mexican patent?
In which countries has InMed (INM) filed patent applications for its cannabinoid analogs?
How many patent families does InMed Pharmaceuticals (INM) currently maintain?
